15/01/2026
ZAP Surgical has announced a landmark clinical research collaboration exploring a new, non-invasive approach for treatment-resistant depression.
The Precision Radiomodulation Therapy Project for Depression will evaluate the safety and feasibility of low-dose, non-ablative stereotactic radiotherapy using the ZAP-X platform. The study targets the subgenual anterior cingulate cortex, a key brain region involved in mood regulation.
Key highlights:
• First clinical evaluation of precision radiomodulation for severe depression using ZAP-X
• Non-ablative, low-dose stereotactic radiotherapy designed to modulate neural circuits rather than destroy tissue
• Fully non-invasive, outpatient treatment with no implants or anesthesia
• IRB-approved clinical trial with enrollment expected in early 2026
This carefully designed research program reflects a responsible expansion of radiosurgery technology beyond traditional oncologic applications and into functional brain disorders.
While radiomodulation is not a cleared indication for stereotactic radiosurgery, this study represents an important step toward generating high-quality clinical evidence for future non-invasive neuromodulation therapies.
